Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
104 Results for "
complement inhibitors
" in MedChemExpress (MCE) Product Catalog:
Products (104)
104 Results for "complement inhibitors" in MCE Product Catalog:
13
13 Publications Verification
Synonyms: LNP023
Target:
Forschungsgebiete:
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
13
13 Publications Verification
Synonyms: LNP023 hydrochloride
Target:
Forschungsgebiete:
Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
7
Target:
Forschungsgebiete:
7
Target:
Forschungsgebiete:
7
Target:
Forschungsgebiete:
5
5 Cited Publications
Synonyms: DSS (MW 5000); DXS (MW 5000)
5
Target:
Forschungsgebiete:
Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
5
5 Cited Publications
Synonyms: ACH-4471
Target:
Forschungsgebiete:
Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
5
5 Cited Publications
Target:
Forschungsgebiete:
JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 μM) and reduces TNF levels (EC50=4.5 μM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases .
4
4 Cited Publications
Art. -Nr.: HY-P9914
CAS. Nr.: 219685-50-4
Synonyms: Anti-Human C5, Humanized Antibody; h5G1.1
Target:
Forschungsgebiete:
Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology
3
3 Cited Publications
Art. -Nr.: HY-P1036
CAS. Nr.: 206645-99-0
Target:
Forschungsgebiete:
3
3 Cited Publications
Art. -Nr.: HY-P1036A
Target:
Forschungsgebiete:
2
2 Cited Publications
Art. -Nr.: HY-N9481
CAS. Nr.: 56411-57-5
2
2 Cited Publications
Art. -Nr.: HY-A0183
CAS. Nr.: 1446756-47-3
Synonyms: Phospholipids, phosphatidylserines; Serine glycerophosphatides
Category:
Target:
2
2 Cited Publications
Synonyms: ALXN2050; ACH 0145228; ACH-5228
Target:
Forschungsgebiete:
Vemircopan (ALXN2050) is an orally active complement factor D (FD) inhibitor. Vemircopan can be used in the research of diseases such as myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria .
1
1 Cited Publications
Art. -Nr.: HY-P3252A
Target:
Forschungsgebiete:
1
1 Cited Publications
Art. -Nr.: HY-P9976
CAS. Nr.: 1461640-62-9
Synonyms: ch38SB19; hu38SB19; SAR-650984
1
1 Cited Publications
Art. -Nr.: HY-P9976A
CAS. Nr.: 1461640-62-9
1
Target:
Forschungsgebiete:
1
1 Cited Publications
Target:
Forschungsgebiete:
Compound C5-IN-1 (Compound 7) is a selective allosteric inhibitor of complement component protein C5. Compound C5-IN-1 prevents C5 from being cleaved by C5 convertase, inhibits the cleavage of C5 into C5a and C5b, and thus blocks the formation of membrane attack complex (MAC). Compound C5-IN-1 has an IC50 of 0.77 μM and 5 nM in 50% human whole blood and 2% human serum to block MAC deposition induced by zymosan, respectively. Compound C5-IN-1 can be used to study diseases related to complement overactivation, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
